SPRYCEL Receives CHMP Positive Opinion For The Treatment Of Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML In Chronic Phase

Posted by rob on October 25, 2010 under Uncategorized | Comments are off for this article

Bristol-Myers Squibb today announced that SPRYCEL (dasatinib) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive Chronic Myelogenous Leukaemia in Chronic Phase (CML-CP)… (Source: Health News from Medical News Today)
More